6-Propylamino-9-methylpurin | 35234-62-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 6-Propylamino-9-methylpurin
• 英文别名: 9-Methyl-6-propylaminopurin；N-Propyl-9-methyladenin；(9-methyl-9H-purin-6-yl)-propyl-amine；9-Methyl-n-propyl-9h-purin-6-amine；9-methyl-N-propylpurin-6-amine
• CAS: 35234-62-9
• 化学式: C₉H₁₃N₅
• 分子量: 191.236
• InChiKey: KGVDZSITWBPXTJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6-氯-4-甲基嘧啶-4,5-二胺,6-氯-4-甲基-4,5-二氨基嘧啶 在 乙酸酐 作用下， 生成 6-Propylamino-9-methylpurin
  参考文献：
  名称：

  Potential Purine Antagonists. IV. Synthesis of Some 9-Methyl-6-substituted-purines¹

  摘要：

  DOI：

  10.1021/ja01559a069

文献信息

• CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF
  申请人：SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD.

  公开号：US20210340169A1

  公开（公告）日：2021-11-04

  Provided are a compound of formula (I), an optical isomer thereof, a pharmaceutically acceptable salt thereof, uses of said compound acting as a STING agonist.

  提供的是化合物（I）的化学式，其光学异构体，其药用盐，以及作为STING激动剂的该化合物的用途。
• [EN] LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSITIONS LIPIDIQUES POUR L'ADMINISTRATION DE COMPOSÉS AGONISTES DE STING ET LEURS UTILISATIONS
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2021216572A1

  公开（公告）日：2021-10-28

  The present disclosure provides lipid compositions comprising lipid particles (e.g., lipid nanodiscs), wherein the lipid particles (e.g., lipid nanodiscs) comprise a STING agonist amphiphile conjugate, a phospholipid and a PEG-lipid. The compositions are used in methods to induce or promote immune responses, such as immune responses useful for the treatment of cancer or infectious disease.

  本公开提供了包含脂质粒子（例如脂质纳米盘）的脂质组合物，其中脂质粒子（例如脂质纳米盘）包含STING激动剂两亲分子共轭物、磷脂和PEG-脂质。该组合物用于诱导或促进免疫反应，例如用于治疗癌症或传染病的免疫反应。
• CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION
  申请人：Shanghai de Novo Pharmatech Co., Ltd.

  公开号：EP3854799A1

  公开（公告）日：2021-07-28

  A cyclic dinucleotide analogue, a pharmaceutical composition thereof, and application. A cyclic dinucleotide analogue (I), an isomer thereof, a prodrug, a stable isotope derivative, or a pharmaceutically acceptable salt has the following structure. The cyclic dinucleotide analogue can be used as a regulator of a stimulator of interferon genes (STING) and a related signal path thereof, and can effectively treat and/or relieve multiple types of diseases, including but not limited to malignant tumors, inflammations, autoimmune diseases, and infectious diseases. In addition, the STING regulator can also be used as a vaccine adjuvant.

  一种环二核苷酸类似物、其药物组合物及应用。一种环二核苷酸类似物（I）、其异构体、原药、稳定同位素衍生物或药学上可接受的盐具有如下结构。环二核苷酸类似物可用作干扰素基因刺激物（STING）及其相关信号通路的调节剂，可有效治疗和/或缓解多种类型的疾病，包括但不限于恶性肿瘤、炎症、自身免疫性疾病和传染性疾病。此外，STING 调节剂还可用作疫苗佐剂。
• Cyclic di-nucleotide compounds as STING agonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10738074B2

  公开（公告）日：2020-08-11

  A class of polycyclic compounds of general formula (II), of general formula (II′), or of general formula (II″), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3a, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.

  一类通式(II)、通式(II′)或通式(II″)的多环化合物，其中Base1、Base2、Y、Ya、Xa、Xa1、Xb、Xb1、Xc、Xc1、Xd、Xd1、R1、R1a、本文定义了 R2、R2a、R3a、R4、R4a、R5、R6、R6a、R7、R7a、R8 和 R8a，它们可用作 I 型干扰素产生的诱导剂，特别是 STING 活性剂。还提供了合成和使用这些化合物的工艺。
• CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20170044206A1

  公开（公告）日：2017-02-16

  A class of polycyclic compounds of general formula (I), of general formula (I′), or of general formula (I″), wherein Base 1 , Base 2 , Y, Y a , X a , X a1 , X b , X b1 , X c , X c1 , X d , X d1 , R 1 , R 1a , R 2 , R 2a , R 3 , R 4 , R 4a , R 5 , R 6 , R 6a , R 7 , R 7a , R 8 , and R 8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.